Shares of Amgen were falling Tuesday after the biotechnology company easily beat quarterly earnings estimates and lifted revenue guidance.
Third-quarter sales of inflammation drug Amjevita/Amgevita rose 30% year-over-year, bolstered by 53% volume growth, partially offset by lower prices, according to the release, while sales of Prolia, one of Amgen’s general medicine treatments, jumped 14% from a year ago, boosted by a 7% uptick in volume and higher prices.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
ソース: MarketWatch - 🏆 3. / 97 続きを読む »
Arista Stock Jumps as Earnings Top EstimatesInvestors had worried about the outlook after Meta Platforms issued a more conservative capital-spending forecast than expected.
ソース: MarketWatch - 🏆 3. / 97 続きを読む »
Dow jumps more than 300 points ahead of Fed rate decision, earningsCertain parts of the economy have proved to be resilient, spurring concerns that the central bank could signal willingness to hold rates at their current level for longer than previously anticipate…
ソース: nypost - 🏆 91. / 67 続きを読む »